Impel Pharmaceuticals Gross Profit

The latest gross profit for IMPL is $11M as of September 2023. That compares with $3.5M in the prior-year period — up 215.1% year over year. That is below the Healthcare sector average of $4.3T. Investors often review this figure alongside Impel Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMPL's gross profit moved from $3.5M to $11M — a 215.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Impel Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, IMPL currently prints $11M for gross profit, while the sector average sits near $4.3T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Impel Pharmaceuticals's growth, margins, and balance sheet.

A gross profit figure of $11M for IMPL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $4.3T. Explore the charts below for those layers of context.

After noting IMPL's gross profit ($11M), review year-over-year change from $3.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.